Unknown

Dataset Information

0

Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients.


ABSTRACT: Neuroblastoma (NB) is a deadly childhood disease that carries a 50% chance of relapse for anyone in remission and similar level of 5-year survival. We investigated the value of our proprietary approach-cell surface vimentin (CSV) positive circulating tumor cells (CTC) to monitor treatment response and predict relapse in NB patients under remission in a Phase II long-term preventative clinical trial. We longitudinally analyzed peripheral blood samples from 93 patients for 27?cycles (~25?months) and discovered that the presence of CSV+ CTCs in the first two sequential samples (baseline, cycle 4 [month 3-4]) was a significant indicator of earlier relapse. We observed strong correlation between relapse-free survival (RFS) and lack of CSV+ CTCs in first 4 cycles of therapy (95%). There was sensitivity reaching 100% in predicting RFS in patients who had neither CSV+ CTCs nor MycN amplification. Of note, the low number of CSV+ CTCs seems equivalent to low tumor load because the prevention therapy difluoromethylornithine yields faster reduction of relapse risk when none or only 1-2 CSV+ CTCs (every 6 mL) are present in the blood samples compared to >3 CSV+ CTCs. To the best of our knowledge, this is the first study that directly observes CTCs in under remission NB patients for relapse prediction and the first to gather sequential CSV+ CTC data in any study in a long-term longitudinal manner.

SUBMITTER: Batth IS 

PROVIDER: S-EPMC7839076 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients.

Batth Izhar S IS   Dao Long L   Satelli Arun A   Mitra Abhisek A   Yi Sofia S   Noh Hyangsoon H   Li Heming H   Brownlee Zachary Z   Zhou Shouhao S   Bond Jeffrey J   Wang Jing J   Gill Jonathan J   Sholler Giselle S GS   Li Shulin S  

International journal of cancer 20200623 12


Neuroblastoma (NB) is a deadly childhood disease that carries a 50% chance of relapse for anyone in remission and similar level of 5-year survival. We investigated the value of our proprietary approach-cell surface vimentin (CSV) positive circulating tumor cells (CTC) to monitor treatment response and predict relapse in NB patients under remission in a Phase II long-term preventative clinical trial. We longitudinally analyzed peripheral blood samples from 93 patients for 27 cycles (~25 months) a  ...[more]

Similar Datasets

| S-EPMC7138401 | biostudies-literature
| S-EPMC8695931 | biostudies-literature
| S-EPMC4929464 | biostudies-literature
| S-EPMC5649080 | biostudies-literature
| S-EPMC5564771 | biostudies-literature
| S-EPMC4360893 | biostudies-literature
| S-EPMC8618087 | biostudies-literature
| S-EPMC8509386 | biostudies-literature
| S-EPMC6551451 | biostudies-literature
| S-EPMC7555811 | biostudies-literature